DNLI Denali Therapeutics Inc

$18.00

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.

Website: https://www.denalitherapeutics.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1714899
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, US
Valuation
Market Cap
$1.85B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.50
Performance
EPS
$-2.57
Dividend Yield
—
Profit Margin
0.00%
ROE
-37.40%
Technicals
50D MA
$16.18
200D MA
$22.58
52W High
$33.33
52W Low
$10.57
Fundamentals
Shares Outstanding
145M
Target Price
$36.44
Beta
1.58

DNLI EPS Estimates vs Actual

● Estimated
● Actual

DNLI News & Sentiment

Nov 07, 2025 • Zacks Commentary NEUTRAL
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
Nov 03, 2025 • Benzinga SOMEWHAT-BULLISH
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson's, and Neuroimmune Disorders
EXTON, PA, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Spherix Global Insights' latest Special Topix™: Neurology Pipeline Opportunities 2025 ( US ) service captures forward-looking insights from 79 U.S. neurologists across five key neurological conditions-Amyotrophic Lateral Sclerosis ( ALS ) , ...
Oct 14, 2025 • Benzinga NEUTRAL
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Denali Therapeutics ( NASDAQ:DNLI )
The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) review timeline of the Biologics License Application ( BLA ) , seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II ( MPS II ) , also known as Hunter ...
Oct 14, 2025 • Zacks Commentary NEUTRAL
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Oct 13, 2025 • Benzinga NEUTRAL
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II ( Hunter Syndrome ) - Denali Therapeutics ( NASDAQ:DNLI )
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Denali Therapeutics Inc. ( NASDAQ:DNLI ) today announced that the U.S.
Sep 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Why Is Denali Therapeutics ( DNLI ) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sentiment Snapshot

Average Sentiment Score:

0.136
50 articles with scored sentiment

Overall Sentiment:

Neutral

DNLI Reported Earnings

Aug 11, 2025
Jun 30, 2025 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: -1.4%
May 06, 2025
Mar 31, 2025 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.78
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: -10.8%
Feb 27, 2025
Dec 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $-0.67
  • Estimate: $-0.85
  • Whisper: —
  • Surprise %: 20.8%
Nov 06, 2024
Sep 30, 2024 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.63
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: -3.3%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $-0.59
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: 14.5%
May 07, 2024
Mar 31, 2024 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.78
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: -11.4%
Feb 27, 2024
Dec 31, 2023 (Pre market)
-0.06 Surprise
  • Reported EPS: $-0.86
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: -7.5%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.08 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: 10.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
1.98 Surprise
  • Reported EPS: $1.30
  • Estimate: $-0.68
  • Whisper: —
  • Surprise %: 291.2%

Financials